HDAC9 and COVID-19: Murthy et al.(Murthy et al., 2021) said that COVID-19 recovered patients who show unresolved patchy areas of opacification, interstitial thickening and early signs of fibrosis during the follow-up chest CT after discharge should be considered for HDAC inhibitors treatment to reduce the possibility of the development of pulmonary fibrosis.